Equitable Trust Co. Acquires 112 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Equitable Trust Co. lifted its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 2.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,213 shares of the medical instruments supplier’s stock after purchasing an additional 112 shares during the quarter. Equitable Trust Co.’s holdings in ICU Medical were worth $950,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of ICU Medical by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after purchasing an additional 11,991 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ICU Medical by 21.7% in the second quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after purchasing an additional 55,588 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its position in shares of ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after purchasing an additional 145,485 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of ICU Medical by 11.5% in the second quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock worth $25,710,000 after purchasing an additional 22,310 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in shares of ICU Medical by 9.3% in the second quarter. Federated Hermes Inc. now owns 215,808 shares of the medical instruments supplier’s stock worth $25,627,000 after purchasing an additional 18,301 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ICUI shares. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. KeyCorp upped their price target on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price target on the stock. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Finally, Raymond James upped their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $170.25.

ICU Medical Price Performance

Shares of ICUI opened at $176.79 on Friday. The firm has a market capitalization of $4.32 billion, a PE ratio of -60.54 and a beta of 0.66. The company’s 50-day moving average is $175.30 and its 200-day moving average is $140.27. ICU Medical, Inc. has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 earnings per share. Equities analysts forecast that ICU Medical, Inc. will post 3.81 EPS for the current year.

Insider Activity

In related news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,502 shares of company stock valued at $8,445,976 over the last ninety days. 6.70% of the stock is currently owned by company insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.